Skip to Content
  • Title
    Company Group Chairman
  • Affiliation
    Johnson & Johnson
  • Age

Taubert is responsible for more than 30% of J&J’s $72 billion in revenue with her oversight of the health care titan’s pharma business in North America and Latin America. Expect the size of her operation to grow as J&J completes its $30 billion acquisition of bio­pharma company ­Actelion. Taubert advocated for the deal, which will add a sixth business unit to J&J’s pharma operations—this one focused on pulmonary hypertension. She also joined J&J’s management committee this year, upping her influence internally.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Personal Information

Previous Rank45

Company Financials (2016, or most recently completed fiscal year)

Revenues ($M)71,890
Profits ($M)16,540
Market Value as of 9/14/17 ($M)